scholarly journals Ultra‐Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse‐Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI‐Naive Patients

2009 ◽  
Vol 199 (9) ◽  
pp. 1275-1285 ◽  
Author(s):  
Severine Margeridon‐Thermet ◽  
Nancy S. Shulman ◽  
Aijaz Ahmed ◽  
Rajin Shahriar ◽  
Tommy Liu ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
B Virus ◽  
Nucleotide Reverse Transcriptase Inhibitor ◽  
Reverse Transcriptase Inhibitor

scholarly journals Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting

2018 ◽  
Vol 5 (10) ◽  
Author(s):  
Adam Abdullahi ◽  
Olga Mafotsing Fopoussi ◽  
Judith Torimiro ◽  
Mark Atkins ◽  
Charles Kouanfack ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Antiretroviral Therapy ◽  
Hepatitis B ◽  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Hbv Dna ◽  
Hbv Infection ◽  
Study Entry ◽  
B Virus ◽  
Reverse Transcriptase Inhibitor

Abstract Background We monitored the evolution of markers of hepatitis B virus (HBV) infection in virologically suppressed HIV-positive patients switching to nucleoside reverse transcriptase inhibitor (NRTI)–sparing antiretroviral therapy within a randomized trial in Cameroon. Methods   HBV surface antigen (HBsAg), HBV DNA, and antibodies against surface (anti-HBs), core (total anti-HBc), and e-antigen (anti-HBe) were measured retrospectively in samples collected at study entry and over 48 weeks after NRTI discontinuation. Results Participants (n = 80, 75% females) had a plasma HIV-1 RNA <60 copies/mL, a median CD4 count of 466 cells/mm3, and undetectable HBsAg and HBV DNA at study entry. After NRTI discontinuation, 3/20 (15.0%) anti-HBc-negative patients showed evidence indicative or suggestive of incident HBV infection (163 cases/1000 person-years); 6/60 (10.0%) anti-HBc-positive patients showed evidence indicative or suggestive of HBV reactivation (109 cases/1000 person-years). In one case of reactivation, anti-HBs increased from 14 to >1000 IU/L; sequencing showed HBV genotype A3 and 3 escape mutations in surface (Y100C, K122R, Y161FY). Alongside new-onset detection of HBsAg or HBV DNA, 1 patient experienced acute hepatitis and 6 patients experienced mild or marginal increases in serum transaminase levels. Conclusions Evolving treatment strategies for sub-Saharan Africa must be accompanied by the formulation and implementation of policy to guide appropriate assessment and management of HBV status.

scholarly journals Adefovir dipivoxil-induced development of osteomalacia and Fanconi syndrome during the treatment of hepatitis B virus (HBV)-related cirrhosis

2014 ◽  
Vol 8 (4) ◽  
pp. 109-114
Author(s):  
Orietta Staltari ◽  
Benedetto Caroleo ◽  
Andzelika Michniewicz ◽  
Giovambattista De Sarro ◽  
Franco Perticone ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Adefovir Dipivoxil ◽  
Fanconi Syndrome ◽  
Pathologic Fracture ◽  
Transcriptase Inhibitor ◽  
B Virus ◽  
Long Time ◽  
Reverse Transcriptase Inhibitor

Adefovir dipivoxil is a nucleotide analog reverse transcriptase inhibitor used to treat adult patients affected by HBeAg-positive and HBeAg-negative chronic hepatitis B and with clinical evidence of lamivudine-resistant hepatitis B virus (HBV). Adefovir administered at a dosage of 10 mg/day is generally well tolerated, even if renal toxicity, type Fanconi syndrome, was reported during long-term treatments.We report a case of osteomalacia with Fanconi syndrome and pathologic fracture of the femur related to long-time (67 months) adefovir treatment (10 mg/day) in a patient with compensated hepatitis B virus (HBV) cirrhosis (Child 5A) and with a previous normal renal function (estimated Glomerular Filtration Rate before adefovir = 78.26 ml/min/1.73 m2; during adefovir treatment = 57.38 ml/min/1.73 m2). The patient was switched to entecavir at a dose of 1 mg/day, with both suppression of viremia and improvement of osteomalacia and Fanconi syndrome; the patient’s follow-up is still ongoing after 22 months.

Low In Vitro Potential for Class-specific Toxicity of GS-9148, A Novel Nucleotide Reverse Transcriptase Inhibitor

2008 ◽  
Vol 78 (2) ◽  
pp. A27
Author(s):  
Genevieve Laflamme ◽  
Constantin Boojamra ◽  
Lijun Zhang ◽  
Hon Hui ◽  
Robyn Fisher ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Nucleotide Reverse Transcriptase Inhibitor ◽  
Reverse Transcriptase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document